Spots Global Cancer Trial Database for azd9291
Every month we try and update this database with for azd9291 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | NCT02972333 | EGFR-TKI Resist... Nonsmall Cell L... AZD9291 Brain Metastase... | AZD9291 80mg or... Radiation thera... | 18 Years - | Shandong Cancer Hospital and Institute | |
| T790M Mutation Positive 2nd Line STandard of cAre Registry | NCT02368990 | Non Small Cell ... | 18 Years - | AstraZeneca | ||
| Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer | NCT02179671 | Locally Advance... | Gefitinib AZD9291 Selumetinib+Doc... Tremelimumab | 18 Years - 130 Years | AstraZeneca | |
| Uncommon EGFR AZD9291 | NCT03424759 | Non Small Cell ... | AZD9291 | 19 Years - | Samsung Medical Center | |
| Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific | NCT02442349 | Non-Small Cell ... | AZD9291 | 18 Years - 130 Years | AstraZeneca | |
| Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | NCT02972333 | EGFR-TKI Resist... Nonsmall Cell L... AZD9291 Brain Metastase... | AZD9291 80mg or... Radiation thera... | 18 Years - | Shandong Cancer Hospital and Institute | |
| Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) | NCT02856893 | NSCLC | Osimertinib Gefitinib | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours | NCT02094261 | Non Small Cell ... | AZD9291 | 18 Years - 130 Years | AstraZeneca | |
| A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291 | NCT02491944 | Oncology | AZD9291 [14C]AZD9291 | 18 Years - 65 Years | AstraZeneca | |
| Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | NCT02908750 | Non Small Cell ... | Fexofenadine ta... Osimertininb ta... | 18 Years - 130 Years | AstraZeneca | |
| AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies | NCT02504346 | Lung Cancer Targeted Therap... | AZD9291 | 18 Years - | Oslo University Hospital | |
| Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours | NCT02094261 | Non Small Cell ... | AZD9291 | 18 Years - 130 Years | AstraZeneca | |
| Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | NCT03778229 | Carcinoma | osimertinib savolitinib placebo | 18 Years - | AstraZeneca | |
| Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA | NCT02811354 | Carcinoma, Non-... | AZD9291 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | NCT02736513 | Lung Cancer | AZD9291 | 18 Years - | Soroka University Medical Center | |
| AZD9291 US Expanded Access Program | NCT02451852 | EGFR T790M Muta... | AZD9291 | 18 Years - 130 Years | AstraZeneca | |
| AZD9291 in Combination With Ascending Doses of Novel Therapeutics | NCT02143466 | Advanced Non Sm... | Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part A - AZD929... Part B - AZD929... Part B - AZD929... Part B - AZD929... Part C - AZD609... Part C - AZD929... Part D - AZD929... | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC | NCT02908750 | Non Small Cell ... | Fexofenadine ta... Osimertininb ta... | 18 Years - 130 Years | AstraZeneca | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291 | NCT02491944 | Oncology | AZD9291 [14C]AZD9291 | 18 Years - 65 Years | AstraZeneca | |
| Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) | NCT02157883 | Advanced Non Sm... Advanced (Inope... | Pharmacokinetic... AZD9291 Itraconazole | 18 Years - 99 Years | AstraZeneca | |
| Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | NCT03778229 | Carcinoma | osimertinib savolitinib placebo | 18 Years - | AstraZeneca | |
| TAURAS - T790 AURA ScreenFailure SOC Registry Study | NCT02405247 | Non Small Cell ... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | NCT02736513 | Lung Cancer | AZD9291 | 18 Years - | Soroka University Medical Center | |
| Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific | NCT02442349 | Non-Small Cell ... | AZD9291 | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
